177785-24-9Relevant academic research and scientific papers
Use of an antagonist of PPAR alpha and PPAR gamma for the treatment of syndrome X
-
, (2008/06/13)
PCT No. PCT/EP97/00058 Sec. 371 Date Sep. 10, 1998 Sec. 102(e) Date Sep. 10, 1998 PCT Filed Jan. 7, 1997 PCT Pub. No. WO97/25042 PCT Pub. Date Jul. 17, 1997A method for the treatment or prophylaxis of Syndrome X in a human or non-human mammal is disclosed. The method comprises the administration of an effective, non-toxic and pharmaceutically effective amount of an agonist of PPAR alpha and PPAR gamma , or a pharmaceutically acceptable derivative thereof, to a human or non-human mammal in need thereof.
Non-thiazolidinedione antihyperglycaemic agents. Part 5: Asymmetric aldol synthesis of (S)-(-)-2-oxy-3-arylpropanoic acids
Haigh, David,Birrell, Helen C.,Cantello, Barrie C. C.,Eggleston, Drake S.,Haltiwanger, R. Curtis,Hindley, Richard M.,Ramaswamy, Anantha,Stevens, Nicola C.
, p. 1353 - 1367 (2007/10/03)
Boron-mediated asymmetric aldol reactions of substituted benzaldehyde 5 with 2-oxyethanoyloxazolidinones 4a-e, containing electron withdrawing, chelating, and bulky alkoxy and aryloxy groups, gave variable yields of syn- aldol adducts 6a-e in high diastereoisomeric excess. Dehydroxylation of these adducts afforded 7a-e in a sequence which complements the traditional Evans asymmetric alkylation strategy. Cleavage of the auxiliary from 7a-e afforded antihyperglycaemic (S)-(-)-2-oxy-3-arylpropanoic acids 3a-e in excellent enantiomeric excess.
